Identification of a highly encapsulated, genetically related group of invasive type III group B streptococci

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 1116-1119

  Takahashi, Shinji ^b   Adderson, Elisabeth E ^b   Nagano, Yukiko ^b   Nagano, Noriyuki ^b   Briesacher, Mark R ^b   Bohnsack, John F ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIAL ENZYME; COMPLEMENT COMPONENT C5A; SIALIC ACID;

ARTICLE; BACTERIAL GENETICS; BACTERIAL MEMBRANE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; NONHUMAN; PRIORITY JOURNAL; RESTRICTION MAPPING; STREPTOCOCCUS AGALACTIAE; VAGINA SMEAR;

EID: 0031969497     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517408     Document Type: Article

References (15)

1. Baker CJ, Edwards MS. Group B streptococcal infections. In: Remington JS, Klein JO, eds. Infectious disease of the fetus and newborn infant. 4th ed. Philadelphia: WB Saunders, 1995;980-1054.
2. Blumberg HM, Stephens DS, Modansky M, et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996;173:365-73.
3. Kogan G, Uhrin D, Brisson JR, et al. Structural and immunochemical characterization of the type VIII group B Streptococcus capsular polysaccharide. J Biol Chem 1996;271:8786-90.
4. Nagano Y, Nagano N, Takahashi S, et al. Restriction endonuclease digest patterns of chromosomal DNA from group B β-haemolytic streptococci. J Med Microbiol 1991;35:297-303.
5. Paoletti LC, Ross RA, Johnson KD. Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide. Infect Immun 1996;64:1220-6.
6. Aminoff D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 1961;81:384-92.
7. Bohnsack JF, Mollison KW, Buko AM, Ashworth JW, Hill HR. Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus. Biochem J 1991;273:635-40.
8. Linden V, Christensen KK, Christensen P. The occurrence of R-protein among isolates of group B streptococci from human sources. Acta Pathol Microbiol Scand [B] 1983;91:153-6.
9. Musser JM, Mattingly SJ, Quentin R, Goudeau A, Selander RK. Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease. Proc Natl Acad Sci USA 1989;86:4731-5.
10. Helmig R, Uldgjerg N, Boris J, Kilian M. Clonal analysis of Streptococcus agalactiae isolated from infants with neonatal sepsis or meningitis and their mothers and from healthy pregnant women. J Infect Dis 1993;168:904-9.
11. Hauge M, Jespersgaard C, Poulsen K, Kilian M. Population structure of Streptococcus agalactiae reveals an association between specific evolutionary lineages and putative virulence factors but not disease. Infect Immun 1996;64:919-25.
12. Takahashi S, Nagano Y, Nagano N, Hayashi O, Taguchi F, Okuwaki Y. Role of C5a-ase in group B streptococcal resistance to opsonophagocytic killing. Infect Immun 1995;63:4764-9.
13. Bohnsack JF, Widjaja K, Ghazizadeh S, et al. A role for C5 in the acute neutrophil response to group B streptococcal infections. J Infect Dis 1997;175:847-55.
14. Edwards ME, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative pathway by type III, group B streptococci. J Immunol 1982;128:1278-83.
15. Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun 1992;60:3986-93.